The development of anti-MT1-MMP RICscould overcome a major challenge in FGS of sarcoma that stems fromthe use of probes that lack specificity for molecular biomarkers ofsarcoma, leading to improved resection margins and better patientoutcomes. This evidence concerns the gene MMP14 and sarcoma.